A randomized controlled trial of high-dose maintenance interferon therapy in chronic hepatitis C

Journal of Medical Virology

Volumn 51, Issue 1, 1997, Pages 17-24

  Di Marco, Vito ^a   Lo Iacono, Oreste ^a   Cammà, Calogero ^c   Almasio, Piero L ^a   Vaccaro, Alessandra ^b   Fuschi, Patrizia ^a   Giunta, Marco ^b   Fabiano, Carmelo ^b   Pagliaro, Luigi ^b   Craxì, Antonio ^a,d  

^a Istituto di Clinica Medica   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c CNR   (Italy)

^d Cattedra di Medicina Interna   (Italy)

Author keywords

chronic hepatitis; cirrhosis; genotype; HCV; interferon therapy; prolonged high dose; sustained response

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; BIOPSY; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON ALFA-2B; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET COUNT; RECURRENCE; RNA, VIRAL; TIME FACTORS; TRANSAMINASES;

EID: 18244427901     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199701)51:1<17::AID-JMV3>3.0.CO;2-V     Document Type: Article

References (37)

1. Booth JCL, Foster GR, Kumar U, Galassini R, Goldin RD, Brown JL, Thomas HC (1993): Chronic hepatitis C virus infections: Predictive value of genotype and level of viraemia on disease progression and response to interferon. Gut 36:427-432.
2. Camps J, Castilla A, Ruiz J, Civeira MP, Prieto J (1993a): Randomized trial of lymphoblastoid-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. Journal of Hepatology 17:390-396.
3. Camps J, García N, Riezu-Boj JI, Civeira MP, Prieto J (1993b): Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. Journal of Hepatology 19:408-412.
4. Caporaso N, Suozzo R, Morisco F, D'Antonio M, Romano M, Coltorti M (1993): Recombinant human interferon alpha-2a therapy for chronic hepatitis C with or without cirrhosis: Comparison of 3 or 6 MU for 1 year. Italian Journal of Gastroenterology 25:482-486.
5. Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C (1991): Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 101:497-502.
6. Chemello L, Alberti A, Rose K, Simmonds P (1994): Hepatitis C serotype and response to interferon therapy. New England Journal of Medicine 330:143.
7. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, Frezza M, Noventa F, Pontisso P, Benvegnù L, Casarin C, Alberti A, the TriVeneto Viral Hepatitis Group (1995): Randomized trial comparing three differnt regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 22:700-706.
8. Cox DR (1970): "The Analysis of Binary Data." London: Methuen.
9. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, Jacobson IM, Payne J, Dienstag JL, VanThiel DH, Tamburro C, Lefkowitch J, Albrecht J, Meschievitz C, Ortego TJ, Gibas A, The hepatitis International Therapy Group (1989): Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. New England Journal of Medicine. 321:1501-1506.
10. De Bac C, Grimaldi F, Clementi C, Duca F, Livoli D, Taliani G (1993): Efficacy of different regimens of interferon alfa-2b treatment in chronic hepatitis C. Gut 34(Suppl.):S135.
11. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ (1994): Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 19:1513-1520.
12. Di Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Bancks SM, Hoofnagle JH (1989): Recombinant interferon alfa for chronic hepatitis C. A randomized, double-blind, placebo-controlled clinical trial. New England Journal of Medicine 321:1506-1510.
13. 2a: Results of a randomized controlled clinical trial. Hepatology 19:1-5.
14. Garson JA, Brillanti S, Ring C, Perini P, Miglioli M, Barbara L (1992): Hepatitis C viraemia rebound after "successful" interferon therapy in patients with chronic non-A, non-B hepatitis. Journal of Medical Virology 37:210-214.
15. Hagiwara H, Hayashi N, Mita E, Takeara T, Kasahara A, Fusamoto H, Kamada T (1993): Quantitative analysis of hepatitis C virus RNA in serum during interferon alfa therapy. Gastroenterology 104:877-883.
16. Iino S, Hino K, Kuroki T, Suzuki H, Yamamoto S (1993): Treatment of chronic hepatitis C with high-dose interferon alpha-2b: A multicenter study. Digestive Diseases and Sciences 38:612-618.
17. Janssen HLA, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S (1993): Fatal hepatic decompensation associated with interferon alfa. British Medical Journal 306:107-108.
18. Jouët P, Roudot-Thoraval F, Dhumeaux D, Métreau J-M, French Group Study Chronic Hepatitis (1994): Comparative efficacy of interferon alfa in cirrhotic and noncirrhotic patients with non-A, non-B, C hepatitis. Gastroenterology 106:686-690.
19. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y (1993): A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 105:507-512.
20. Kanai K, Kako M, Okamoto H (1992): HCV genotypes in chronic hepatitis C and response to interferon. Lancet 339:1543.
21. Kasahara A, Hayashi N, Hiramatsu N, Oshita M, Hagiwara H, Katayama K, Kato M, Masuzawa M, Yoshihara H, Kischida Y, Shimizu Y, Inoue A, Fusamoto H, Kamada T (1995): Ability of prolonged interferon treatment to suppress relapse after cessation of therapy in patients with chronic hepatitis C: A multicenter randomized controlled trial. Hepatology 21:291-297.
22. Koskinas J, Tibbs C, Saleh MG, Pereira LMMB, McFarlane IG, Williams R (1995): Effects of ribavirin in intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients. Journal of Medical Virology 45:29-34.
23. Lin R, Roach E, Zimmerman M, Strasser S, and Farrell GC for the Australia Hepatitis C Study Group (1995): Interferon alfa-2b for chronic hepatitis C: Effects of dose increment and duration of treatment on response rates. Journal of Hepatology 23:487-496.
24. Magrin S, Craxì A, Fabiano C, Fiorentino G, Marino L, Almasio P, Pinzello GB, Palazzo U, Vitale M, Maggio A, Bucca G, Gianguzza F, Shymala V, Han JH, Pagliaro L (1992): Serum HCV-RNA and response to alpha-interferon in anti-HCV positive chronic hepatitis. Journal of Medical Virology 38:200-206.
25. Magrin S, Craxì A, Fabiano C, Marino L, Fiorentino G, Di Marco V, Lo Iacono O, Almasio P, Urdea MS, Wilber JH, Stuyver L, Pagliaro L (1994): HCV viraemia, viral genotypes and response to IFN in patients with chronic hepatitis C from Sicily. Journal of Hepatology 21:S24.
26. 2a therapy in patients with chronic hepatitis C. Digestive Diseases and Sciences 39:1273-1280.
27. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P, Abate ML, Zahm F, Dastoli G, Ballarè M, Riffy YG, Verme G, Bonino F (1994): Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 107:479-485.
28. Niederau C, Heintges T, Häussinger D (1995): Treatment of chronic NANB and C hepatitis with α-interferon: A meta-analysis of dose and duration. Hepatology 22:153A.
29. Pagliaro L, Craxì A, Cammà C, Tinè F, Di Marco V, Lo Iacono O, Almasio P (1994): Interferon for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 19:820-828.
30. Poynard T, Leroy V, Cohard M, Mathurin P, Opolon P, Zarski JP (1995a): Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration. Hepatology 22:113A.
31. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trpo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M, Chaput JC and the Multicenter Study Group (1995b): A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. New England Journal of Medicine 332:1457-1462.
32. Sáez-Royuela F, Porres JC, Moreno A, Castillo I, Martinez G, Galiana F, Carreno V, (1991): High doses of recombinant alfa-interferon or gamma-interferon for chronic hepatitis C: A randomized, controlled trial. Hepatology 13:327-331.
33. SAS Institute, Inc. (1988) "SAS/STAT User's Guide. Release 6.03." Cary, NC: SAS Institute, Inc., pp 189-282.
34. Schvarcz R, Yun ZB, Sönnerborg A, Weiland O (1995): Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. Journal of Medical Virology 46:43-47.
35. Simmonds P, Rose KA, Graham S, Chan S-W, McOmih F, Dow BC, Follett EAC, Yap PL, Marsden H (1993): Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): Use of type-specific peptides to serologically differentiate infections with HCV types 1, 2, and 3. Journal of Clinical Microbiology 31:1493-1503.
36. Tinè F, Magrin S, Craxì A, Pagliaro L (1991): Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. Journal of Hepatology 13:192-199.
37. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Sitoh S, Hashimoto M, Iwasaki Satomi, Kobayashi M, Hiromitsu K (1994): Factors predictive of response to interferon-alfa therapy in hepatitis C virus infection. Hepatology 19:1088-1094.